Incyte Corporation (NASDAQ:INCY) on Monday shared topline results from the pivotal Phase 3 frontMIND trial of tafasitamab (Monjuvi/Minjuvi) combo as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL).

The trial evaluated tafasitamab and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) compared to R-CHOP alone.

The trial met its primary endpoint of progression-free survival (PFS). The trial also met its key secondary endpoint of event-free survival (EFS) by investigator assessment. No new safety signals were observed.

Also Read: Incyte’s New Therapy Shows Signs Of ‘Disease-Modifying’ Potential In Rare Blood Cancer

DLBCL is the most common type of non-Hodgkin lymphoma (NHL) in adults worldwide, representing 40% of all cases. It is characterized as an aggressive, fast-growing type of lymphoma that can emerge in lymph nodes ...